These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11521785)

  • 1. A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer.
    Içli F; Akbulut H; Dinçol D; Onur H; Demirkazik A; Cam R; Cay F; Demirci S; Uner A; Erekul S
    Ann Oncol; 2001 Jul; 12(7):1011-3. PubMed ID: 11521785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
    Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla JP; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
    J Clin Oncol; 2001 Feb; 19(3):612-20. PubMed ID: 11157010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
    Shulman LN; Cirrincione CT; Berry DA; Becker HP; Perez EA; O'Regan R; Martino S; Atkins JN; Mayer E; Schneider CJ; Kimmick G; Norton L; Muss H; Winer EP; Hudis C
    J Clin Oncol; 2012 Nov; 30(33):4071-6. PubMed ID: 22826271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung.
    Shaw EG; Frytak S; Eagan RT; Richardson RL; Creagan ET; Jett JR; Foote RL; Su JQ; Schaid DJ; Lee RE
    Am J Clin Oncol; 1996 Apr; 19(2):154-8. PubMed ID: 8610640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
    Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
    J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
    Hortobagyi GN; Buzdar AU; Theriault RL; Valero V; Frye D; Booser DJ; Holmes FA; Giralt S; Khouri I; Andersson B; Gajewski JL; Rondon G; Smith TL; Singletary SE; Ames FC; Sneige N; Strom EA; McNeese MD; Deisseroth AB; Champlin RE
    J Natl Cancer Inst; 2000 Feb; 92(3):225-33. PubMed ID: 10655439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
    Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
    Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
    J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.